Edition:
United Kingdom

AngioDynamics Inc (ANGO.OQ)

ANGO.OQ on NASDAQ Stock Exchange Global Select Market

21.10USD
19 Nov 2018
Change (% chg)

-- (--)
Prev Close
$21.10
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
72,073
52-wk High
$24.49
52-wk Low
$15.16

Latest Key Developments (Source: Significant Developments)

AngioDynamics Q1 Adjusted Earnings Per Share $0.16
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - AngioDynamics Inc ::ANGIODYNAMICS REPORTS FISCAL 2019 FIRST QUARTER FINANCIAL RESULTS.Q1 ADJUSTED EARNINGS PER SHARE $0.16.Q1 GAAP LOSS PER SHARE $0.01.SEES FY 2019 SALES $354 MILLION TO $359 MILLION.Q1 SALES $85.3 MILLION VERSUS I/B/E/S VIEW $84 MILLION.Q1 EARNINGS PER SHARE VIEW $0.18 -- THOMSON REUTERS I/B/E/S.SEES FY 2019 ADJUSTED EARNINGS PER SHARE $0.82 TO $0.86.CURRENCY DID NOT HAVE SIGNIFICANT IMPACT ON CO'S SALES IN QUARTER.SAYS UPDATING FINANCIAL GUIDANCE TO REFLECT BIOSENTRY AND RADIADYNE ACQUISITIONS AND PAYMENT MADE TO DOJ.  Full Article

Angiodynamics Inc Sees FY 2019 Rev $348 Mln To $353 Mln
Thursday, 6 Sep 2018 

Sept 6 (Reuters) - AngioDynamics Inc ::SEES FY 2019 REVENUE $348 MILLION TO $353 MILLION.FY2019 REVENUE VIEW $345.2 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

AngioDynamics Q3 Earnings Per Share $0.37
Thursday, 29 Mar 2018 

March 29 (Reuters) - AngioDynamics Inc ::ANGIODYNAMICS REPORTS FISCAL 2018 THIRD QUARTER FINANCIAL RESULTS.Q3 ADJUSTED EARNINGS PER SHARE $0.25.Q3 GAAP EARNINGS PER SHARE $0.37.Q3 SALES $83.9 MILLION VERSUS I/B/E/S VIEW $84.8 MILLION.Q3 EARNINGS PER SHARE VIEW $0.19 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 SALES $345 MILLION TO $350 MILLION.SEES 2018 ADJUSTED EARNINGS PER SHARE $0.70 TO $0.74.ANGIODYNAMICS - ‍ EXPECTS ITS ADJUSTED EARNINGS PER SHARE IN RANGE OF $0.64 TO $0.68, EXCLUDING ANY IMPACT FROM 2017 TAX REFORM ACT​ FOR FY 2018.FY2018 EARNINGS PER SHARE VIEW $0.71, REVENUE VIEW $346.6 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Angiodynamics Receives FDA Expedited Access Pathway Designation For Nanoknife System For Treatment Of Stage III Pancreatic Cancer
Wednesday, 24 Jan 2018 

Jan 24 (Reuters) - Angiodynamics Inc ::ANGIODYNAMICS RECEIVES FDA EXPEDITED ACCESS PATHWAY DESIGNATION FOR THE NANOKNIFE® SYSTEM FOR THE TREATMENT OF STAGE III PANCREATIC CANCER.ANGIODYNAMICS INC - ‍FDA GRANTED EXPEDITED ACCESS PATHWAY DESIGNATION TO COMPANY'S NANOKNIFE SYSTEM​.  Full Article

AngioDynamics Says U.S. Tax Reform To Have Impact Of $0.02- $0.04 On Non-GAAP Adjusted EPS In FY 2018
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - AngioDynamics Inc ::ANGIODYNAMICS SAYS U.S. TAX REFORM ACT TO HAVE AN IMPACT IN RANGE OF $0.02- $0.04 ON NON-GAAP ADJUSTED EPS IN FY 2018 -SEC FILING.  Full Article

AngioDynamics Q2 GAAP Earnings Per Share $0.01
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - AngioDynamics Inc ::ANGIODYNAMICS REPORTS FISCAL 2018 SECOND QUARTER FINANCIAL RESULTS.Q2 ADJUSTED EARNINGS PER SHARE $0.16.Q2 GAAP EARNINGS PER SHARE $0.01.SEES FY 2018 SALES $345 MILLION TO $350 MILLION.Q2 SALES $86.7 MILLION VERSUS I/B/E/S VIEW $88.4 MILLION.Q2 EARNINGS PER SHARE VIEW $0.16 -- THOMSON REUTERS I/B/E/S.REAFFIRMS FY 2018 ADJUSTED EARNINGS PER SHARE VIEW $0.64 TO $0.68 EXCLUDING ITEMS.FOR 2018, COMPANY IS REDUCING ITS PREVIOUSLY ANNOUNCED NET SALES AND FREE CASH FLOW GUIDANCE.CO NOW EXPECTS ITS FISCAL YEAR 2018 NET SALES IN RANGE OF $345 TO $350 MILLION.  Full Article

AngioDynamics to pay $12.5 mln over false claims allegations -U.S. Justice Dept

WASHINGTON, July 18 AngioDynamics Inc has agreed to pay the U.S. government $12.5 million to resolve allegations it caused healthcare providers to submit false claims to federal healthcare programs over the use of two medical devices, the Justice Department said on Wednesday.